Nipocalimab was granted U.S. FDA Breakthrough Therapy Designation for the treatment of adults living with moderate-to-severe Sjögren's disease based on results from the Phase 2 DAHLIAS study ...

The two companies will present a joint poster highlighting this workflow at the upcoming ... Savara Inc. (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, ...

SeaStar Medical Holding Corporation (Nasdaq: ICU) ("SeaStar Medical" or the "Company"), a commercial-stage medical device company developing proprietary solutions ...

In November 2024 we received FDA Breakthrough Device Designation for the SCD for use in chronic dialysis, our first such designation for a chronic indication. This is our fourth FDA award of ...

Revenues increased 17% compared to the previous quarter ended June 30, 2024Strengthened balance sheet is expected to provide sufficient cash ...

Pratteln, Switzerland, November 12, 2024 – Santhera Pharmaceuticals (SIX: SANN) announces the signing of an exclusive supply agreement with Ali Al Suwaidi Trading Est. (ASTE) for the treatment of ...

High dose TSHA-102 was generally well tolerated with no SAEs or DLTs in two adolescent/adult patients and one <a target=_blank href= ...

Rainforest protection is not only good for biodiversity and the climate—it also noticeably improves the health of humans who ...

Coughing, sneezing and sniffling are rising in the Valley due to respiratory illnesses. Walking pneumonia is especially ...

Infectious and non-infectious respiratory diseases are regarded as accelerated-age conditions in which chronic inflammation, exacerbated/dysregulated immune responses, and immunological senescence ...

Fall is upon us, and along with the cooler weather and changing leaves, we are expecting to see an increase in respiratory ...